SynthesisRenal failure2021
Efficacy of statins on renal function in patients with chronic kidney disease: a systematic review and meta-analysis.
Synthesis in Renal failure, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Genetic association analysis of lipid-lowering drug target genes in chronic kidney disease.Frontiers in endocrinology · 2024Pooled it
- Atorvastatin reduces recurrent decompensation events in advanced cirrhosis in a randomized placebo-controlled trial.Scientific reports · 2026Trial
- Effects of statins on kidney function in older adults.Journal of the American Geriatrics Society · 2025Trial
- The role of protein prenylation in kidney diseases: Molecular basis and therapeutic implications.Molecular biology reports · 2026Review
- Moving Mendelian Randomization From Traditional Risk Factors to Molecular Targets for Drug Development and Clinical Trials in Nephrology.Kidney international reports · 2026Review
- Article
- ESKD, Major Cardiovascular Events, and Death Associated With Systemic Inflammation.Kidney international reports · 2026Article
- Lipids in kidney diseases: from systemic imbalance to intrarenal alterations of cellular lipid metabolism in rare and common kidney diseases.Journal of molecular medicine (Berlin, Germany) · 2026Review
- Reno-protective effects of statins among patients with chronic kidney disease in Hong Kong: a target trial emulation.EClinicalMedicine · 2026Article
- Safety Profile of Statins: An Umbrella Review of Systematic Reviews and Meta-analyses.European cardiology · 2026Review
- Predictors of rapid eGFR decline in early to moderate chronic kidney disease (stages G1-G4): insights from a real-world Thai cohort incorporating KDIGO 2024 guidelines.Renal failure · 2025Article
- Characteristics and outcomes in atorvastatin therapy for chronic subdural hematoma: a national, observational real-world study in China, 2019-2024.The Lancet regional health. Western Pacific · 2025Article
- Chronic kidney disease in the primary care setting: A narrative review.Journal of general and family medicine · 2025Review
- Atorvastatin Confers Renoprotection and Modulates Inflammation in Diabetic Rats on a High-Fat Diet.Life (Basel, Switzerland) · 2025Article
- Renal Safety Assessment of Lipid-Lowering Drugs: Between Old Certainties and New Questions.Drugs · 2025Review
- Statin Use in Special Populations for the Prevention of Cardiovascular Disease in Adults.Current atherosclerosis reports · 2025Review
- Action of 3-Hydroxy-3-Methylglutaryl-CoA Reductase Inhibitors on ABCA-1 protein (ATP-Binding Cassette Transporter-1) in endothelial cells stimulated with uremic serum.Lipids in health and disease · 2025Article
- Effects ofJournal of experimental pharmacology · 2025Article
- Diabetic kidney disease: from pathogenesis to multimodal therapy-current evidence and future directions.Frontiers in medicine · 2025Review
- Effect of statins and antihyperglycemics on chronic kidney disease in patients with type 2 diabetes mellitus: a retrospective cohort study with a 12-year follow-up.Journal of pharmaceutical policy and practice · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStudies have shown that the use of statins could significantly improve lipid profiles; however, it remains controversial whether the use of statins could improve renal function in patients with chronic kidney disease (CKD). Therefore, we conducted a meta-analysis of randomized controlled trials (RCTs) to evaluate the effects of statins on renal function in patients with CKD.
methodsWe systematically searched PubMed, EMBASE, and the Cochrane Library databases for eligible RCTs from inception to October 2020. Pooled effect estimates were assigned as weighted mean differences (WMDs) with 95% confidence intervals (CIs) using the random-effects model.
resultsWe selected 33 RCTs that recruited 37,391 patients with CKD patients. The summary results suggested that statin use significantly reduced urinary albumin (WMD: -2.04; 95%CI: -3.53 to -0.56;
conclusionsWe found that statin use in patients with CKD may slow CKD progression by lowering urinary albumin and protein excretions or increasing creatinine clearance. Further large-scale RCTs should be conducted to evaluate the long-term effects of statins on renal outcomes.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.